No Detail Found!

Evaluation of alpha Klotho and fibroblast growth factor- 23 levels in Iraqi patients with Graves' disease

Author(s)
Munaf Faraj Rashid Department of Medical Chemistry, College of Medicine, University of Al-Qadisiyah,,Iraq
Haider Abd Jabbar Alammar Department of Clinical Biochemistry, College of Medicine, University of Al-Qadisiyah,,Iraq
Abbas Mahdi Rahmah National Diabetes Center, Mustansiriyah University,,Iraq
Abstract
Background & Objective: Graves' disease (GD) is an autoimmune condition that targets the thyroid gland, resulting in excessive stimulation and synthesis of thyroid hormones. Excessive synthesis of these hormones can lead to symptoms such as loss of body weight, accelerated heart rate, irritability, reduced tolerance to heat, and excessive perspiration. Alpha-Klotho (KL), a protein crucial for physiological processes, is also involved in GD. The defective immunological condition of GD patients may increase Klotho expression, and the enhanced expression of fibroblast growth factor-23 (FGF23) in GD may be linked to the disease pathophysiology. We investigated serum levels of KL and FGF23 in Iraqi patients with Graves' disease, analyzing correlations with clinical status and evaluating their potential as biomarkers for disease activity. Methodology: We conducted this cross-sectional study at The National Diabetes Center, Mustansiriyah University, between December 2022 and April 2023. The study involved 103 patients diagnosed with GD, and 103 patients, aged 21-70 y, as a control group. Patients with multinodular goiter, single thyroid nodules, thyroiditis, pregnant women, and those on medications or oral contraceptives, were excluded. Result: clinical significance of FGF23 and Klotho (KL) levels in patients with Graves' disease (GD) compared to a control group. Results indicate that the median of KL levels are significantly higher in GD patients (KL = 6.31) compared to the control group (KL = 2.40), with a highly significant difference (P < 0.001). In contrast, differences in median of FGF23 levels between GD patients (149) and controls (86.05) were not statistically significant (P = 0.07). Furthermore, KL levels were significantly higher in hyperthyroid patients compared to other thyroid statuses (P = 0.023), while FGF23 levels did not significantly differ across thyroid statuses (P = 0.255). Additionally, the study found a strong correlation between TRAb levels and both KL (r = 0.291, P < 0.001) and FGF23 (r = 0.211, P = 0.003), and between KL and FGF23 directly (r = 0.412, P < 0.001). These findings suggest that while KL may be a significant biomarker in GD, FGF23 relevance appears limited in this context. Conclusion: In Graves' Disease patients have significantly higher levels of KL and FGF23 compared to controls, suggesting a distinct pathophysiological role for these biomarkers in mineral homeostasis and thyroid hormone regulation. Abbreviations: AITD - Autoimmune thyroid diseases; KL - Alpha-Klotho; FGF23 - fibroblast growth factor-23; GD Graves' disease; HT - Hashimoto's thyroiditis; IGF-1R - Insulin-like Growth Factor-1 Receptor;
Publication Details
Page(s) 836-841
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 28, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
Hyperthyroidism, autoimmune thyroid disorders, Hyperthyroidism, Graves' disease, Alpha-Klotho
References
.2018 .. , 05(12) : 1169-75.
Salah RB,Kacem FH,Soomauro S,Chouaib S,Frikha F,Charfi N . .Autoimmune thyroiditis associated with autoimmune 3. , : .
Ek M,Roth B,Nilsson PM,Ohlsson B .2018 .Characteristics of endometriosis: A case-cohort study showing elevated IgG titers against the TSH receptor (TRAb) and mental comorbidity. Eur J Obstet Gynecol Reprod Biol, 09 : 8.
Neag E,Smith T. 2021 .2022 .update on thyroid-associated ophthalmopathy. J Endocrinol Invest, 45(2) : 235-59.
. .. [PubMed] DOI: 10.1007/s40618-021-01663-9, : .
Marín-Sánchez A,Álvarez-Sierra D,González O,Lucas-Martin A,Sellés-Sánchez A,Rudilla F .2019 .Regulation of TSHR expression in the thyroid and thymus may contribute to TSHR tolerance failure in Grave's disease patients via two distinct mechanisms. Front Immunol, 10 : 1695.
Khan MS,Lone SS,Faiz S,Farooq I,Majid S .2021 .Disease: Pathophysiology, Genetics and Management. , 10 : .
Antonelli A,Fallahi P,Rotondi M,Ferrari SM,Romagnani P,Grosso M . .Increased serum CXCL10 in Grave's disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol., : .
.2006 .. , 154(5) : 02137-8.
Pokhrel B,Bhusal K. Graves,Disease K. Graves .2024 .. , : .
Antonelli A,Fallahi P,Elia G,Ragusa F,Paparo SR,Ruffilli I .2020 .Grave's disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab, 34(1) : 101388.
Mace ML,Olgaard K,Lewin E .2020 .New aspects of the kidney in the regulation of fibroblast growth factor 23 (FGF23) and mineral homeostasis. Int J Mol Sci, 21(22) : 8810.
Erben RG .2018 .. Physiological actions of fibroblast growth factor-23. Front Endocrinol, 267 : .
Agoro R,Ni P,Noonan ML,White KE .2020 .Osteocytic FGF23 and its kidney function. Front Endocrinol, 11 : 592.
Rayego-Mateos S,Doladé N,García-Carrasco A,Diaz-Tocados JM,Ibarz M,Valdivielso JM .2022 .The increase in FGF23 induced by calcium is partially dependent on vitamin D signaling. , 14(13) : 2576.
Goltzman D,Feingold KR,Anawalt B,Blackman MR .2000 .. , : .
Lin CH,Chang CK,Shih CW,Li HY,Chen KY,Yang WS .2019 .Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Grave's diseases: A case-control study. Osteoporos Int, 30(11) : 2289-97.
Huang C-L,Moe OW .2021 .Soluble α-klotho-a fibroblast growth factor 23-independent hormone. Fibroblast Growth Factor, 23 : 233-40.
Hanson K,Fisher K,Hooper NM .2021 .Exploiting the neuroprotective effects of α-klotho to tackle ageing-and neurodegenerationrelated cognitive dysfunction. Neuronal Signal, 5(2) : .
Bellido T,Pajevic PD,Bonewald L. Osteocyte,Biology L. Osteocyte . .. Genetics of Bone Biology and Skeletal Disease: Elsevier; 2018, : 227-40.
Wang W,Su Y,Xu J,Yao W,Qin Q,He S .2018 .Elevated serum concentrations of FGF23 and Klotho in patients with Grave's disease and their significance. Clin Med China, 06 : 6315-4.
Kuro-o M. .2013 .Klotho, phosphate and FGF23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol, 9(11) : 650-60.
Yuan Q,Shen F,Chen B .2018 .FGF23 as a new biomarker for differentiating Graves' disease and Hashimoto's thyroiditis. J Endocrinol Invest, 41(2) : 149-57.
Kadooh QA,Al-Ziaydi AG,Hamza AJ .2024 .Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines. Menopause Rev, 10(2) : 57-63.
0

Citations

0

Downloads

69

Views